Premium
Targeted therapy and pharmacogenomic programs
Author(s) -
Iqbal Syma,
Lenz Heinz Josef
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11287
Subject(s) - medicine , pharmacogenomics , oncology , profiling (computer programming) , clinical trial , gene expression profiling , pharmacogenetics , bioinformatics , toxicity , pharmacology , gene expression , gene , biology , genetics , computer science , genotype , operating system
The goal in administering chemotherapeutics is to develop the ability to predict the outcome of therapy in terms of response and toxicity. Technology has been developed to allow tumor profiling with measurement of protein expression, gene expression levels of markers, and even genetic polymorphisms, which may predict response to particular chemotherapeutics. The chemotherapeutics for which particular markers have been shown to predict outcome include the fluoropyrimidines and platinums. The next step is to develop clinical trials that will assess prospectively the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity. Cancer 2003;97(8 Suppl):2076–82. © 2003 American Cancer Society. DOI 10.1002/cncr.11287